Business Context and Reporting Period
This Form 8-K is a current report filed by AntriaBio, Inc. (not Rezolute, Inc.) on March 22, 2017, covering events occurring on March 17, 2017. The filing discloses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of two new independent directors to the Board of Directors:
- Tae Hoon Kim: Former Chief Operating Officer at Aju Pharm and experienced professional from Genentech, Inc.
- Samir R. Patel, M.D.: Co-founder and CEO of Digital Therapeutics, LLC and former CEO of SPEC Pharma, LLC. Dr. Patel has invested approximately $2 million in the Company.
No compensatory agreements were entered into with the new directors at the time of appointment.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies are disclosed in this report. The information is furnished under Regulation FD and is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is AntriaBio, Inc., not Rezolute, Inc.
- Confirm the independence status of the new directors under NYSE MKT LLC Company Guide Section 803A.
- Monitor future filings for potential committee assignments for the new directors.
- Note that Dr. Patel's $2 million investment represents a significant financial commitment by a new board member.